We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Myelin-maker: How an FDA-approved drug boosts myelin synthesis
News

Myelin-maker: How an FDA-approved drug boosts myelin synthesis

Myelin-maker: How an FDA-approved drug boosts myelin synthesis
News

Myelin-maker: How an FDA-approved drug boosts myelin synthesis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Myelin-maker: How an FDA-approved drug boosts myelin synthesis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Transplanted human stem cells treated with drug boost myelin synthesis and improve auditory function in a preclinical study

Damage to myelin, the fatty insulator that enables communication between nerve cells, characterizes multiple sclerosis (MS) and other devastating neurological diseases.


The damage doesn’t come all at once: There is a “honeymoon” period during which some regeneration of myelin, called remyelination, does occur, but this ability to regenerate dissipates as the disease progresses and the patient ages.


Now, a University at Buffalo researcher has discovered a way to keep that kind of remyelination going, using a drug that’s already on the market.


A paper describing the research results was published in the Journal of Neuroscience.


“We have identified a new drug target that promotes stem cell therapy for myelin-based disease, such as MS,” says lead author Fraser J. Sim, PhD, assistant professor in the Department of Pharmacology and Toxicology in the University at Buffalo School of Medicine and Biomedical Sciences.


The study shows it is possible to boost myelination by targeting human oligodendrocyte progenitor cells with solifenacin, an anti-muscarinic drug that currently is approved and marketed to treat overactive bladder.


“Our hypothesis is that in MS, the oligodendrocyte progenitor cells seem to get stuck,” Sim explains. “When these cells don’t mature properly, they don’t differentiate into myelinating oligodendrocytes.”


In the new study, the approach Sim and his colleagues took was to first characterize the molecular pathways that govern the differentiation of human oligodendrocyte progenitor cells, and then identify drug candidates that would promote differentiation and myelin production.


They found that when a muscarinic type 3 receptor on human oligodendrocyte progenitor cells was activated, differentiation was completely blocked.


 “So we thought, if we had something that blocks instead of activates this receptor, could we boost differentiation?” asks Fraser. To do that, the researchers turned to solifenacin, the anti-muscarinic drug for overactive bladder; the bladder muscle contains several muscarinic receptors.


“We were excited about this because solifenacin is an approved drug that’s already on the market,” says Sim.


To test whether the drug could boost myelin synthesis, the researchers transplanted human oligodendrocyte progenitor cells into mice that could not make myelin. The result was increased differentiation and myelin synthesis from the transplanted human cells.


But Sim and his colleagues needed a functional endpoint, a way to know that the myelin being made was being translated into improved behavior or function.


So Sim teamed up with Richard J. Salvi, PhD, SUNY Distinguished Professor in the Department of Communicative Disorders and Sciences, and director of UB’s Center for Hearing and Deafness.


Together, they determined that an auditory brainstem response, which records brain wave activity in response to sounds, would be appropriate.


Sim explains that it takes a certain amount of time for a signal to go from the ear to the front of the brain: “So in the readout, you get waves that should have a certain time pattern. When there isn’t enough myelin, the signaling slows down. And if you add myelin, you should see the signals speed up.”


The tests showed improvement in the response to auditory signals in animals transplanted with the human oligodendrocyte progenitor cells treated with solifenacin.


“We have identified a way to improve human myelination,” says Sim.


The promising results have prompted Sim and his colleagues to seek funding for a small human trial.


The study results are all preclinical and no human testing has been done yet.


Note: Material may have been edited for length and content. For further information, please contact the cited source.

University at Buffalo   Original reporting by: Ellen Goldbaum


Publication

Kavitha Abiraman, Suyog U. Pol, Melanie A. O'Bara, Guang-Di Chen, Zainab M. Khaku, Jing Wang, David Thorn, Bansi H. Vedia, Ezinne C. Ekwegbalu, Jun-Xu Li, Richard J. Salvi, Fraser J. Sim. Anti-Muscarinic Adjunct Therapy Accelerates Functional Human Oligodendrocyte Repair.   Journal of Neuroscience, Published February 25 2015. doi: 10.1523/JNEUROSCI.3510-14.2015


Advertisement